Name: R411
Type: small molecule
Groups: investigational
Indication: Investigated for use/treatment in asthma.
Accession Number: DB05468 ( DB05468)
Description: R411 is a non-steroid oral medicine for the treatment of asthma. It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory inflammation. It is a dual-acting competitive integrin antagonist (as compared to previously developed single integrin antagonists or SIAs) that prevents binding of V-CAM1 to either a4b1 or a4b7.
Prescription Products: Not Available
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
  • No Brands

Brand Names
  • No Brands

Brand Mixtures
Brand NameIngredients

  • No Category


Indication: Investigated for use/treatment in asthma.
Pharmacodynamics: Not Available
Mechanism of action: R411 prevents binding of V-CAM1 to either a4b1 or a4b7.
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half life: Not Available
Clearance: Not Available
Toxicity: Good safety profile observed in preclinical and clinical studies
Affected organisms
  • Not Available

SNP Mediated Adverse Drug Reactions
  • Not Available


  • Not Available

  • Not Available

Dosage forms

Unit descriptionCostUnit

CountryPatent NumberApprovedExpires (estimated)


Drug Interactions

Food Interactions:
  • Not Available


Kingdom: Not Available
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
  • Not Available

  • Not Available


Synthesis Reference: Not Available
General Reference: # Hijazi Y, Welker H, Dorr AE, Frank K, Renzetti LM, Patel I: Evaluation of the effect of multiple-dose administration of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist on the major CYP isoform activities in healthy volunteers. Eur J Clin Pharmacol. 2006 Jan;62(1):83-5. Epub 2005 Dec 21. "Pubmed": # Hijazi Y, Welker H, Dorr AE, Tang JP, Blain R, Renzetti LM, Abbas R: Pharmacokinetics, safety, and tolerability of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers. J Clin Pharmacol. 2004 Dec;44(12):1368-78. "Pubmed":
External Links:

ATC Codes:
  • Not Available

AHFS Codes:
  • Not Available

MSDS: Download

© Copyright 2022 The Purple Society, Purple Gladiator, Trialsmap, The Purple Drug Guide, and One Person CAN Make A Difference! are all registered trademarks of The Purple Society. The Purple Society, a not-for-profit, section 501(c)(3) #273785281.

The Purple Society website is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through this site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.


The Purple Society team is here for you 24 hours a day, 7 days a week. Send us an email and we'll get right back to you.


Log in with your credentials

Forgot your details?